Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated May 2026
Meta Title: How TRT Affects Your Cholesterol and Lipid Profile
Meta Description: Learn how testosterone replacement therapy affects HDL, LDL, triglycerides, and Lp(a). What TRT men need to monitor for heart health.
This article breaks down exactly how TRT interacts with each major lipid marker, explains why HDL function matters more than HDL concentration, highlights the surprising benefit of testosterone on Lp(a), and tells you what tests men on TRT should actually be tracking.
What you'll learn:
• How TRT affects HDL, LDL, triglycerides, and total cholesterol
• Why HDL concentration is an incomplete measure of cardiovascular risk
• How testosterone lowers Lp(a) - the 'quiet killer' most doctors never test
• What the landmark TRAVERSE trial and the 2025 FDA label change mean for men on TRT
• Which lipid tests and imaging tools should be part of your TRT monitoring protocol
Dose matters enormously. At therapeutic doses equivalent to roughly 100-150 mg per week of injectable testosterone, studies show little to no clinically meaningful drop in HDL. Significant HDL suppression is primarily associated with supraphysiological doses used in bodybuilding contexts, and especially with 17-alpha alkylated oral steroids such as stanozolol, oxandrolone, methyltestosterone, and oxymetholone. Those compounds are a different category entirely.
Members in our community have documented this pattern firsthand. Real-world data shared on ExcelMale shows that members running well-dialed TRT protocols - without aromatase inhibitor overuse or high doses - often report stable or improved lipid panels over time.
Drugs designed to dramatically raise HDL - including CETP inhibitors such as torcetrapib - doubled HDL concentration but failed completely to reduce cardiovascular events. This clinical failure confirmed what researchers suspected: the number on your lab report does not tell you whether your HDL is actually working.
A 2017 study published in Circulation found that testosterone and estradiol regulate HDL particle size independently. Testosterone modestly reduced HDL concentration, but the key measure of efflux capacity was not significantly impaired. In fact, estradiol - produced through aromatization of testosterone - showed a positive association with HDL particle size. This is a compelling reason why men on TRT who also maintain healthy estradiol levels are unlikely to experience meaningful cardiovascular harm from modest HDL changes.
A 2021 systematic review in Cells confirmed that CEC is a better predictor of cardiovascular events than HDL-C concentration, and is impaired primarily by conditions like diabetes, chronic kidney disease, and autoimmune disease - not by therapeutic testosterone.
TRT Effects on Lipid Markers: A Summary
These improvements appear to be driven, at least in part, by the body composition changes that TRT enables: increased lean mass, reduced visceral fat, and improved insulin sensitivity. Testosterone improves the HOMA-IR score (a measure of insulin resistance), which cascades into better lipid metabolism across the board. In men who were already metabolically healthy at baseline, effects on LDL and triglycerides tend to be neutral.
A useful benchmark is the triglyceride-to-HDL ratio. When triglycerides are low and HDL is adequate, this ratio stays favorable and reflects a lower burden of small dense LDL particles - the truly atherogenic fraction. TRT, by improving both triglycerides and body composition, generally helps rather than hurts this ratio in men who need it most.
One important distinction: oral testosterone preparations that undergo significant hepatic first-pass metabolism tend to have less favorable effects on lipids compared to injectable or transdermal routes. This is because they exert stronger effects on hepatic lipase activity, the enzyme that breaks down HDL particles. Transdermal and injectable forms largely bypass this pathway.
Lipoprotein(a), or Lp(a), is a genetically determined variant of LDL that carries an additional protein called apolipoprotein(a). This protein mimics plasminogen - the molecule that breaks down blood clots - but cannot actually perform that function. As a result, high Lp(a) leaves the body in a chronically pro-thrombotic state: clots form more easily and dissolve less readily. Lp(a) also promotes inflammation and is an independent driver of aortic valve calcification.
Unlike standard LDL, Lp(a) is almost entirely determined by genetics. Diet, exercise, and most medications - including statins - have little impact on it. Statins, in some patients, can actually raise Lp(a) slightly.
Testosterone is one of the few agents that reliably lowers Lp(a). A study published in the American Journal of Cardiology found that testosterone reduced Lp(a) by an average of 37% through a direct androgenic mechanism - not through its conversion to estradiol. The addition of an aromatase inhibitor did not significantly alter this benefit, confirming it is androgen-driven. Separate data from the bodybuilding literature found that men using anabolic androgenic steroids had significantly lower Lp(a) compared to non-users, despite worse HDL profiles overall.
Given that elevated Lp(a) affects approximately 20-25% of the global population and is a leading cause of premature cardiovascular events in people who otherwise have 'normal' cholesterol panels, this androgenic benefit of testosterone is clinically underappreciated. Men on TRT who have high Lp(a) at baseline may be receiving cardioprotection from this mechanism that no statin can replicate.
Most standard lipid panels do not include Lp(a). You have to request it specifically. At DiscountedLabs.com, men can order Lp(a) testing directly without needing a physician's order. For men on TRT, testing Lp(a) at baseline and annually is a reasonable part of cardiovascular monitoring.
If your Lp(a) is elevated, high-dose niacin (1-3 g/day) remains one of the few lifestyle-accessible tools to reduce it, though it should be used with medical supervision. Investigational drugs targeting Lp(a) directly - including pelacarsen (TQJ230) and muvalaplin - are in late-stage clinical trials and may become available in the coming years.
The TRAVERSE trial changed that. It was a multicentre, randomized, double-blind, placebo-controlled trial enrolling 5,246 men aged 45 to 80 with confirmed hypogonadism and either existing cardiovascular disease or high cardiovascular risk. This was the most rigorous cardiovascular safety trial ever conducted for TRT - the kind of study the FDA had demanded.
The result: no statistically significant increase in major adverse cardiovascular events (MACE) - defined as heart attack, stroke, or cardiovascular death - in the TRT group compared to placebo. In February 2025, the FDA acted on this data and removed the cardiovascular risk language from the black box warning on testosterone product labels, requiring instead that the TRAVERSE results be included in labeling.
The Androgen Society, in their position statement published in Mayo Clinic Proceedings, noted that observational studies over the past decade have consistently found no credible evidence of increased cardiovascular disease with therapeutic TRT. The Society further highlighted that TRT has shown improvements in lipid profiles, blood glucose, and blood pressure - all markers relevant to cardiovascular health.
It is worth emphasizing that the TRAVERSE trial was conducted in men with existing or high risk of cardiovascular disease - the population where the concern had always been greatest. Therapeutic TRT at physiological doses was found to be non-inferior to placebo across this high-risk group.
• Test once at baseline; it rarely changes significantly over time unless you are on testosterone or niacin therapy. If elevated, recheck annually.Lp(a):
• Aim for under 2.0. A ratio above 3.0 signals insulin resistance and an atherogenic small-dense LDL pattern.Triglyceride-to-HDL ratio:
• Insulin resistance is a more powerful driver of vascular disease than LDL in many men. Know your metabolic baseline.HbA1c or fasting glucose:
• A marker of vascular inflammation that complements lipid data.hsCRP (high-sensitivity C-reactive protein):
• More predictive of risk than LDL-C concentration alone, particularly in men with metabolic syndrome or high triglycerides.LDL particle number (LDL-P) or ApoB:
• Characterizes LDL particle size and HDL particle concentration. Large LDL particles with high HDL particles represent the most favorable pattern.Advanced lipid panel (NMR or ion mobility):
In our experience at ExcelMale, men who take their cardiovascular monitoring seriously tend to get CAC scored in their 40s or 50s as a baseline, track their Lp(a), and use the triglyceride-to-HDL ratio as a quick proxy for metabolic health. This approach provides far more actionable information than chasing a lower LDL number in isolation.
• Reducing refined carbohydrates and sugars is the most effective dietary intervention for lowering triglycerides and improving the triglyceride-to-HDL ratio. Both approaches also reduce insulin resistance - the primary driver of small dense LDL and vascular inflammation.Low-carbohydrate or Mediterranean-style diet:
• A 2025 meta-analysis confirmed that combined training (resistance + cardio) is optimal for lipid management. Each additional weekly aerobic session reduced total cholesterol by approximately 7.68 mg/dL. Exercise also improves HDL efflux capacity independent of HDL concentration.Resistance training plus aerobic exercise:
• If HDL has dropped significantly after starting TRT, the first question is whether the dose is appropriate. Working with your prescriber to dial in the lowest effective dose that maintains symptom relief and optimal free testosterone often resolves lipid concerns without stopping therapy.Dose optimization:
• Research from our community - and the Circulation study cited above - shows that excessive estradiol suppression with AI use worsens the HDL profile and removes the cardiovascular protective effects of estradiol. Manage estradiol; do not eliminate it.Avoid excessive aromatase inhibitor use:
• 2-4 grams daily of EPA and DHA significantly reduce triglycerides and may modestly lower Lp(a). Prescription-strength formulations (Vascepa, Lovaza) are available if dietary sources are insufficient.Omega-3 fatty acids (EPA/DHA):
• High-dose niacin (1-3 g/day) remains one of the only accessible agents for Lp(a) reduction. Use extended-release forms to reduce flushing, and coordinate with your physician.Niacin for elevated Lp(a):
• Testosterone (or Anastrozole?) Decreased My HDL: What Can I Do? - Discussion of the dose-dependent nature of HDL reduction, the role of estradiol, and practical strategies to support HDL levels.
• TRT and Cardiovascular Disease - Comprehensive thread reviewing clinical trial evidence on TRT and cardiovascular outcomes, including coronary calcium score data.
• Testosterone and Estradiol Mediate HDL Particle Size - Discussion of the Circulation 2017 study showing testosterone lowers HDL concentration but not efflux capacity, with estradiol modulating particle size.
• Lipoprotein(a) - Dr. Steven Nissen - Video discussion with Cleveland Clinic cardiologist Dr. Nissen on the genetics, pathophysiology, and clinical management of elevated Lp(a).
• Why You Need a Calcium Score to Know Your Real Heart Risk - Dr. Matthew Budoff - Expert discussion on why CAC scoring is one of the strongest predictors of cardiovascular events and how it complements lipid testing for men on TRT.
• Testosterone and Your Heart: What a Major New Study Really Found - ExcelMale analysis of recent cardiovascular research distinguishing therapeutic TRT from supraphysiological AAS use.
• Does Testosterone Increase the Chance for a Heart Attack? - Early deep-dive thread reviewing the evidence landscape on TRT and cardiac risk, including CAC score trial data and meta-analyses.
• 2026 Guideline on the Management of Dyslipidemia - ExcelMale coverage of the latest AHA/ACC dyslipidemia guidelines, including updated Lp(a) recommendations.
• Impact of Clomiphene Citrate Therapy on Lipid Profiles in Men with Hypogonadism - Study discussion showing that clomiphene also reduces HDL in hypogonadal men - a useful comparison for understanding how HPG axis hormones interact with lipid metabolism.
2. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023;389:107-117 (TRAVERSE Trial). DOI/Link
3. Zmunda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone Decreases Lipoprotein(a) in Men. American Journal of Cardiology. 1996;77(14):1244-7. DOI/Link
4. Bhasin S, et al. Testosterone and Estradiol Mediate Discrete Effects on High-density Lipoprotein Particle Size and Sterol Efflux Capacity in Healthy Men. Circulation. 2017;136 (Suppl 1):A14585. DOI/Link
5. Morgentaler A, et al. Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy. Mayo Clinic Proceedings. 2024. DOI/Link
6. Zitzmann M, et al. Cardiovascular Safety of Testosterone Therapy - Insights from the TRAVERSE Trial and Beyond: A Position Statement of the European Expert Panel for Testosterone Research. Andrology. 2026. DOI/Link
7. Li X, et al. Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis. Journal of Diabetes Research. 2020. DOI/Link
8. Adorni MP, et al. High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease. Cells. 2021;10(3):574. DOI/Link
9. Irvine A, et al. Lipoprotein(a): The Neglected Risk Factor in Cardiovascular Health. Frontiers in Cardiovascular Medicine. 2026. DOI/Link
10. Doewes RI, et al. The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis. PLOS ONE. 2025. DOI/Link
The forum was founded by Nelson Vergel, a chemical engineer and long-term TRT patient with more than 34 years of personal experience with hormone therapy. Nelson is the author of Testosterone: A Man's Guide and Beyond Testosterone, and the founder of DiscountedLabs.com, which provides direct-access laboratory testing for men managing their hormone health.
ExcelMale content is evidence-grounded, peer-reviewed, and written from the perspective of men who have lived the challenges and breakthroughs of TRT firsthand. Join the conversation at ExcelMale.com.
Meta Title: How TRT Affects Your Cholesterol and Lipid Profile
Meta Description: Learn how testosterone replacement therapy affects HDL, LDL, triglycerides, and Lp(a). What TRT men need to monitor for heart health.
Key Takeaways |
• Therapeutic TRT doses (equivalent to 100-150 mg/week) cause minimal or no reduction in HDL cholesterol; large drops are mainly seen with AAS abuse or supraphysiological doses. • Long-term TRT tends to lower LDL, total cholesterol, and triglycerides - especially in men with pre-existing metabolic syndrome. • Testosterone reduces Lp(a) by up to 37% through a direct androgenic mechanism - a clinically meaningful benefit most other treatments cannot match. • HDL function (cholesterol efflux capacity) matters more than HDL concentration on a lab report; TRT's modest HDL dip may not reflect real cardiovascular risk. • The TRAVERSE trial (5,246 men) confirmed no increase in major adverse cardiovascular events (MACE) with TRT, and the FDA removed its cardiovascular black box warning in 2025. • Men on TRT should monitor a full lipid panel including Lp(a), and consider a coronary artery calcium (CAC) score for a direct assessment of plaque burden. |
How Does Testosterone Therapy Affect Your Cholesterol and Lipid Profile?
If you've started testosterone replacement therapy (TRT) and your doctor flagged a drop in your HDL cholesterol, you're not alone. Lipid changes are one of the most frequently asked-about topics in our community - and one of the most misunderstood. The good news: the full picture is considerably more favorable than a single lab value suggests.This article breaks down exactly how TRT interacts with each major lipid marker, explains why HDL function matters more than HDL concentration, highlights the surprising benefit of testosterone on Lp(a), and tells you what tests men on TRT should actually be tracking.
What you'll learn:
• How TRT affects HDL, LDL, triglycerides, and total cholesterol
• Why HDL concentration is an incomplete measure of cardiovascular risk
• How testosterone lowers Lp(a) - the 'quiet killer' most doctors never test
• What the landmark TRAVERSE trial and the 2025 FDA label change mean for men on TRT
• Which lipid tests and imaging tools should be part of your TRT monitoring protocol
Does TRT Lower Your HDL Cholesterol - and Should You Worry About It?
This is the question men ask most often, and the answer depends heavily on dose and duration. In short-term studies, exogenous testosterone does tend to reduce HDL cholesterol modestly. However, long-term TRT studies tell a different story: HDL levels either stabilize or improve over time, while LDL and triglycerides tend to decrease.Dose matters enormously. At therapeutic doses equivalent to roughly 100-150 mg per week of injectable testosterone, studies show little to no clinically meaningful drop in HDL. Significant HDL suppression is primarily associated with supraphysiological doses used in bodybuilding contexts, and especially with 17-alpha alkylated oral steroids such as stanozolol, oxandrolone, methyltestosterone, and oxymetholone. Those compounds are a different category entirely.
Members in our community have documented this pattern firsthand. Real-world data shared on ExcelMale shows that members running well-dialed TRT protocols - without aromatase inhibitor overuse or high doses - often report stable or improved lipid panels over time.
Why HDL Concentration Is Not the Whole Story
Here is something your cardiologist may not have mentioned: HDL cholesterol concentration is a poor predictor of individual cardiovascular risk. What actually matters is HDL function - specifically, the ability of HDL particles to pull cholesterol out of artery-wall macrophages and transport it back to the liver. This process is called cholesterol efflux capacity (CEC).Drugs designed to dramatically raise HDL - including CETP inhibitors such as torcetrapib - doubled HDL concentration but failed completely to reduce cardiovascular events. This clinical failure confirmed what researchers suspected: the number on your lab report does not tell you whether your HDL is actually working.
A 2017 study published in Circulation found that testosterone and estradiol regulate HDL particle size independently. Testosterone modestly reduced HDL concentration, but the key measure of efflux capacity was not significantly impaired. In fact, estradiol - produced through aromatization of testosterone - showed a positive association with HDL particle size. This is a compelling reason why men on TRT who also maintain healthy estradiol levels are unlikely to experience meaningful cardiovascular harm from modest HDL changes.
A 2021 systematic review in Cells confirmed that CEC is a better predictor of cardiovascular events than HDL-C concentration, and is impaired primarily by conditions like diabetes, chronic kidney disease, and autoimmune disease - not by therapeutic testosterone.
TRT Effects on Lipid Markers: A Summary
Lipid Marker | Short-Term TRT Effect | Long-Term TRT Effect | Clinical Significance |
HDL-C | Modest decrease (dose-dependent) | Neutral to improved | Function (efflux capacity) matters more than concentration |
LDL-C | Neutral to decreased | Decreased | Favorable; driven by body composition improvements |
Triglycerides | Neutral to decreased | Decreased | Favorable; especially in metabolic syndrome |
Total Cholesterol | Neutral to decreased | Decreased | Generally favorable long-term trend |
Lp(a) | Decreased by 28-37% | Sustained decrease | Major benefit; androgenic effect, not estradiol-dependent |
How Does TRT Affect LDL, Triglycerides, and Total Cholesterol?
The news on non-HDL lipids is largely positive. A meta-analysis of 18 randomized controlled trials covering 1,415 patients found that TRT significantly reduced both LDL cholesterol and triglycerides, particularly in men with type 2 diabetes or metabolic syndrome. The LDL reduction averaged 0.50 mmol/L and the triglyceride reduction averaged 0.64 mmol/L - not trivial numbers.These improvements appear to be driven, at least in part, by the body composition changes that TRT enables: increased lean mass, reduced visceral fat, and improved insulin sensitivity. Testosterone improves the HOMA-IR score (a measure of insulin resistance), which cascades into better lipid metabolism across the board. In men who were already metabolically healthy at baseline, effects on LDL and triglycerides tend to be neutral.
A useful benchmark is the triglyceride-to-HDL ratio. When triglycerides are low and HDL is adequate, this ratio stays favorable and reflects a lower burden of small dense LDL particles - the truly atherogenic fraction. TRT, by improving both triglycerides and body composition, generally helps rather than hurts this ratio in men who need it most.
One important distinction: oral testosterone preparations that undergo significant hepatic first-pass metabolism tend to have less favorable effects on lipids compared to injectable or transdermal routes. This is because they exert stronger effects on hepatic lipase activity, the enzyme that breaks down HDL particles. Transdermal and injectable forms largely bypass this pathway.
Does Testosterone Lower Lp(a) - the 'Quiet Killer' of Cardiovascular Risk?
This is the part of the TRT-lipid conversation that almost nobody is talking about - and it deserves center stage.Lipoprotein(a), or Lp(a), is a genetically determined variant of LDL that carries an additional protein called apolipoprotein(a). This protein mimics plasminogen - the molecule that breaks down blood clots - but cannot actually perform that function. As a result, high Lp(a) leaves the body in a chronically pro-thrombotic state: clots form more easily and dissolve less readily. Lp(a) also promotes inflammation and is an independent driver of aortic valve calcification.
Unlike standard LDL, Lp(a) is almost entirely determined by genetics. Diet, exercise, and most medications - including statins - have little impact on it. Statins, in some patients, can actually raise Lp(a) slightly.
Testosterone is one of the few agents that reliably lowers Lp(a). A study published in the American Journal of Cardiology found that testosterone reduced Lp(a) by an average of 37% through a direct androgenic mechanism - not through its conversion to estradiol. The addition of an aromatase inhibitor did not significantly alter this benefit, confirming it is androgen-driven. Separate data from the bodybuilding literature found that men using anabolic androgenic steroids had significantly lower Lp(a) compared to non-users, despite worse HDL profiles overall.
Given that elevated Lp(a) affects approximately 20-25% of the global population and is a leading cause of premature cardiovascular events in people who otherwise have 'normal' cholesterol panels, this androgenic benefit of testosterone is clinically underappreciated. Men on TRT who have high Lp(a) at baseline may be receiving cardioprotection from this mechanism that no statin can replicate.
Lp(a) Risk Tiers and Why Every Man on TRT Should Know His Number
Lp(a) Risk ClassificationRisk Category | Lp(a) Level (mg/dL) | Lp(a) Level (nmol/L) | Clinical Action |
Desirable | < 14 | < 35 | Routine monitoring |
Borderline Risk | 14 - 30 | 35 - 75 | Optimize other risk factors; recheck |
High Risk | 31 - 50 | 75 - 125 | Aggressive risk factor management; consider niacin |
Very High Risk | > 50 | > 125 | Specialist referral; investigational Lp(a)-lowering agents if available |
Most standard lipid panels do not include Lp(a). You have to request it specifically. At DiscountedLabs.com, men can order Lp(a) testing directly without needing a physician's order. For men on TRT, testing Lp(a) at baseline and annually is a reasonable part of cardiovascular monitoring.
If your Lp(a) is elevated, high-dose niacin (1-3 g/day) remains one of the few lifestyle-accessible tools to reduce it, though it should be used with medical supervision. Investigational drugs targeting Lp(a) directly - including pelacarsen (TQJ230) and muvalaplin - are in late-stage clinical trials and may become available in the coming years.
What Did the TRAVERSE Trial Actually Show About TRT and Cardiovascular Risk?
For years, men were warned away from TRT based on a handful of flawed retrospective studies that suggested increased cardiovascular risk. In 2015, the FDA added a black box cardiovascular warning to testosterone products - a move that led many physicians to withhold therapy from men who genuinely needed it.The TRAVERSE trial changed that. It was a multicentre, randomized, double-blind, placebo-controlled trial enrolling 5,246 men aged 45 to 80 with confirmed hypogonadism and either existing cardiovascular disease or high cardiovascular risk. This was the most rigorous cardiovascular safety trial ever conducted for TRT - the kind of study the FDA had demanded.
The result: no statistically significant increase in major adverse cardiovascular events (MACE) - defined as heart attack, stroke, or cardiovascular death - in the TRT group compared to placebo. In February 2025, the FDA acted on this data and removed the cardiovascular risk language from the black box warning on testosterone product labels, requiring instead that the TRAVERSE results be included in labeling.
The Androgen Society, in their position statement published in Mayo Clinic Proceedings, noted that observational studies over the past decade have consistently found no credible evidence of increased cardiovascular disease with therapeutic TRT. The Society further highlighted that TRT has shown improvements in lipid profiles, blood glucose, and blood pressure - all markers relevant to cardiovascular health.
It is worth emphasizing that the TRAVERSE trial was conducted in men with existing or high risk of cardiovascular disease - the population where the concern had always been greatest. Therapeutic TRT at physiological doses was found to be non-inferior to placebo across this high-risk group.
What Lipid Tests Should Men on TRT Actually Be Monitoring?
A standard annual lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. For men on TRT, that is a starting point - not the complete picture. Here is what a comprehensive cardiovascular monitoring protocol looks like:Essential Tests
• Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL cholesterol. Run fasting for accuracy, especially on triglycerides.Full fasting lipid panel:• Test once at baseline; it rarely changes significantly over time unless you are on testosterone or niacin therapy. If elevated, recheck annually.Lp(a):
• Aim for under 2.0. A ratio above 3.0 signals insulin resistance and an atherogenic small-dense LDL pattern.Triglyceride-to-HDL ratio:
• Insulin resistance is a more powerful driver of vascular disease than LDL in many men. Know your metabolic baseline.HbA1c or fasting glucose:
• A marker of vascular inflammation that complements lipid data.hsCRP (high-sensitivity C-reactive protein):
Advanced Assessment
• A non-invasive CT scan that directly measures calcified plaque in the coronary arteries. This is the gold standard for knowing your actual plaque burden, not just your estimated risk. Men with a CAC score of zero have an excellent cardiovascular prognosis regardless of LDL level. Multiple trials have shown that TRT does not worsen CAC scores.Coronary Artery Calcium (CAC) Score:• More predictive of risk than LDL-C concentration alone, particularly in men with metabolic syndrome or high triglycerides.LDL particle number (LDL-P) or ApoB:
• Characterizes LDL particle size and HDL particle concentration. Large LDL particles with high HDL particles represent the most favorable pattern.Advanced lipid panel (NMR or ion mobility):
In our experience at ExcelMale, men who take their cardiovascular monitoring seriously tend to get CAC scored in their 40s or 50s as a baseline, track their Lp(a), and use the triglyceride-to-HDL ratio as a quick proxy for metabolic health. This approach provides far more actionable information than chasing a lower LDL number in isolation.
What Lifestyle Strategies Help Men on TRT Maintain Healthy Lipid Profiles?
TRT is not a substitute for a health-supporting lifestyle. The two work together. Men who combine optimized testosterone levels with smart lifestyle practices tend to see the most favorable lipid outcomes.• Reducing refined carbohydrates and sugars is the most effective dietary intervention for lowering triglycerides and improving the triglyceride-to-HDL ratio. Both approaches also reduce insulin resistance - the primary driver of small dense LDL and vascular inflammation.Low-carbohydrate or Mediterranean-style diet:
• A 2025 meta-analysis confirmed that combined training (resistance + cardio) is optimal for lipid management. Each additional weekly aerobic session reduced total cholesterol by approximately 7.68 mg/dL. Exercise also improves HDL efflux capacity independent of HDL concentration.Resistance training plus aerobic exercise:
• If HDL has dropped significantly after starting TRT, the first question is whether the dose is appropriate. Working with your prescriber to dial in the lowest effective dose that maintains symptom relief and optimal free testosterone often resolves lipid concerns without stopping therapy.Dose optimization:
• Research from our community - and the Circulation study cited above - shows that excessive estradiol suppression with AI use worsens the HDL profile and removes the cardiovascular protective effects of estradiol. Manage estradiol; do not eliminate it.Avoid excessive aromatase inhibitor use:
• 2-4 grams daily of EPA and DHA significantly reduce triglycerides and may modestly lower Lp(a). Prescription-strength formulations (Vascepa, Lovaza) are available if dietary sources are insufficient.Omega-3 fatty acids (EPA/DHA):
• High-dose niacin (1-3 g/day) remains one of the only accessible agents for Lp(a) reduction. Use extended-release forms to reduce flushing, and coordinate with your physician.Niacin for elevated Lp(a):
Frequently Asked Questions
If my HDL dropped after starting TRT, should I stop treatment?
Not necessarily, and probably not. A modest HDL drop at therapeutic doses is common in the first few months and often stabilizes or reverses over time. More important is whether your HDL is functionally active (check efflux capacity if you're concerned) and whether your overall lipid pattern - particularly triglycerides, LDL, and the triglyceride-to-HDL ratio - is improving. Large HDL drops (into the 20s or below) are a signal to review your dose and rule out oral anabolic agent use.Does the route of testosterone administration affect lipid profiles?
Yes. Oral testosterone formulations that undergo hepatic first-pass metabolism (such as methyltestosterone) are the most disruptive to lipids. Newer FDA-approved oral formulations like Jatenzo use a lymphatic absorption pathway that reduces liver exposure. Injectable and transdermal forms generally have the most favorable lipid profiles. Subcutaneous injection at lower doses appears to offer excellent lipid stability, as documented by many ExcelMale community members running 70 mg every four days or similar lower-dose protocols.Should men on TRT get a coronary artery calcium score?
Many TRT specialists and preventive cardiologists recommend a baseline CAC score for men over 40, regardless of TRT status. It directly measures plaque - something no blood test can do. Multiple clinical trials have confirmed that TRT does not increase CAC scores compared to placebo. A zero CAC score confers an excellent prognosis even in the presence of elevated LDL or a family history of heart disease. If you have never had one and are in your 40s or 50s, it is worth discussing with your physician.My doctor says TRT is bad for my heart because of my cholesterol. What should I tell him?
Point your physician to the TRAVERSE trial (New England Journal of Medicine, 2023) and the subsequent FDA label change of February 2025, which removed the cardiovascular black box warning. Also share the Androgen Society position statement in Mayo Clinic Proceedings (2024). These are the definitive current evidence summaries. If cholesterol is a specific concern, request a full lipid panel including Lp(a), ask about CAC scoring, and discuss dose optimization. A well-managed TRT protocol at physiological levels is not associated with increased cardiovascular events.Can TRT raise my risk if I already have high cholesterol?
High cholesterol alone is a weaker cardiovascular risk predictor than most people assume, particularly in men over 60 where high LDL is actually associated with longevity in longitudinal studies. More relevant markers are Lp(a), fibrinogen, insulin resistance, and actual plaque burden as measured by CAC score. TRT in hypogonadal men with existing cardiovascular risk was specifically studied in TRAVERSE - and was not associated with increased MACE. Manage modifiable risk factors comprehensively rather than targeting LDL in isolation.Related ExcelMale Forum Discussions
• Has Your Cholesterol Been Affected by TRT? - Community members share real-world lipid panel changes on TRT protocols, including dose comparisons and long-term trends.• Testosterone (or Anastrozole?) Decreased My HDL: What Can I Do? - Discussion of the dose-dependent nature of HDL reduction, the role of estradiol, and practical strategies to support HDL levels.
• TRT and Cardiovascular Disease - Comprehensive thread reviewing clinical trial evidence on TRT and cardiovascular outcomes, including coronary calcium score data.
• Testosterone and Estradiol Mediate HDL Particle Size - Discussion of the Circulation 2017 study showing testosterone lowers HDL concentration but not efflux capacity, with estradiol modulating particle size.
• Lipoprotein(a) - Dr. Steven Nissen - Video discussion with Cleveland Clinic cardiologist Dr. Nissen on the genetics, pathophysiology, and clinical management of elevated Lp(a).
• Why You Need a Calcium Score to Know Your Real Heart Risk - Dr. Matthew Budoff - Expert discussion on why CAC scoring is one of the strongest predictors of cardiovascular events and how it complements lipid testing for men on TRT.
• Testosterone and Your Heart: What a Major New Study Really Found - ExcelMale analysis of recent cardiovascular research distinguishing therapeutic TRT from supraphysiological AAS use.
• Does Testosterone Increase the Chance for a Heart Attack? - Early deep-dive thread reviewing the evidence landscape on TRT and cardiac risk, including CAC score trial data and meta-analyses.
• 2026 Guideline on the Management of Dyslipidemia - ExcelMale coverage of the latest AHA/ACC dyslipidemia guidelines, including updated Lp(a) recommendations.
• Impact of Clomiphene Citrate Therapy on Lipid Profiles in Men with Hypogonadism - Study discussion showing that clomiphene also reduces HDL in hypogonadal men - a useful comparison for understanding how HPG axis hormones interact with lipid metabolism.
Key References
1. Basaria S, et al. Adverse Events Associated with Testosterone Administration. New England Journal of Medicine. 2010;363:109-122. DOI/Link2. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023;389:107-117 (TRAVERSE Trial). DOI/Link
3. Zmunda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone Decreases Lipoprotein(a) in Men. American Journal of Cardiology. 1996;77(14):1244-7. DOI/Link
4. Bhasin S, et al. Testosterone and Estradiol Mediate Discrete Effects on High-density Lipoprotein Particle Size and Sterol Efflux Capacity in Healthy Men. Circulation. 2017;136 (Suppl 1):A14585. DOI/Link
5. Morgentaler A, et al. Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy. Mayo Clinic Proceedings. 2024. DOI/Link
6. Zitzmann M, et al. Cardiovascular Safety of Testosterone Therapy - Insights from the TRAVERSE Trial and Beyond: A Position Statement of the European Expert Panel for Testosterone Research. Andrology. 2026. DOI/Link
7. Li X, et al. Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis. Journal of Diabetes Research. 2020. DOI/Link
8. Adorni MP, et al. High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease. Cells. 2021;10(3):574. DOI/Link
9. Irvine A, et al. Lipoprotein(a): The Neglected Risk Factor in Cardiovascular Health. Frontiers in Cardiovascular Medicine. 2026. DOI/Link
10. Doewes RI, et al. The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis. PLOS ONE. 2025. DOI/Link
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy or medical treatment. Individual responses to testosterone replacement therapy vary based on baseline health, dose, administration route, and comorbidities. |
About ExcelMale
ExcelMale.com is one of the most active and expert-moderated men's health forums on the internet, with more than 24,000 members and 20 years of peer-reviewed discussion on testosterone replacement therapy, hormone optimization, sexual health, and longevity.The forum was founded by Nelson Vergel, a chemical engineer and long-term TRT patient with more than 34 years of personal experience with hormone therapy. Nelson is the author of Testosterone: A Man's Guide and Beyond Testosterone, and the founder of DiscountedLabs.com, which provides direct-access laboratory testing for men managing their hormone health.
ExcelMale content is evidence-grounded, peer-reviewed, and written from the perspective of men who have lived the challenges and breakthroughs of TRT firsthand. Join the conversation at ExcelMale.com.
